Company profile for Vittoria Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vittoria Biotherapeutics is dedicated to realizing the potential of cell therapies and addressing the challenges associated with them. The company's commitment lies in enhancing the efficacy, safety, and therapeutic applicability of cell therapies for patients facing difficult-to-treat diseases. Vittoria Biotherapeutics employs technology that not only improves the effectiveness of cell-based therapeutics but also enhances saf...
Vittoria Biotherapeutics is dedicated to realizing the potential of cell therapies and addressing the challenges associated with them. The company's commitment lies in enhancing the efficacy, safety, and therapeutic applicability of cell therapies for patients facing difficult-to-treat diseases. Vittoria Biotherapeutics employs technology that not only improves the effectiveness of cell-based therapeutics but also enhances safety and expands their utility. This is achieved through various means, including lowering dosing requirements, simplifying preconditioning regimens, minimizing manufacturing failures, and reducing vein-to-vein times.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3675 Market Street Suite 200 Philadelphia, PA 19104
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/10/3184573/0/en/Vittoria-Biotherapeutics-Announces-Presentation-of-First-in-Human-Interim-Phase1-Data-for-VIPER-101-at-ASH2025.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/05/28/3089461/0/en/Vittoria-Biotherapeutics-to-Share-Trials-in-Progress-Presentation-from-Phase-1-Study-of-VIPER-101-at-ASCO-2025-Annual-Meeting.html

GLOBENEWSWIRE
28 May 2025

https://www.globenewswire.com//news-release/2024/12/19/3000160/0/en/Vittoria-Biotherapeutics-Announces-Dosing-of-First-Patient-in-Phase-1-Clinical-Trial-of-VIPER-101.html

GLOBENEWSWIRE
19 Dec 2024

https://www.globenewswire.com/news-release/2024/12/09/2993579/0/en/Vittoria-Biotherapeutics-Presents-Positive-Preclinical-Data-at-66th-Annual-ASH-Meeting-Supporting-its-Novel-Approach-to-Engineered-CAR-T-Cell-Therapies.html

GLOBENEWSWIRE
09 Dec 2024

https://www.globenewswire.com/news-release/2024/11/25/2986623/0/en/Vittoria-Biotherapeutics-Announces-Oral-and-Poster-Presentations-at-the-66th-American-Society-of-Hematology-ASH-Annual-Meeting.html

GLOBENEWSWIRE
25 Nov 2024

https://www.globenewswire.com/news-release/2024/11/12/2978833/0/en/Vittoria-Biotherapeutics-Completes-25-Million-in-Private-Financing-to-Propel-Groundbreaking-Cell-Therapy-Candidates.html

GLOBENEWSWIRE
12 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty